145 related articles for article (PubMed ID: 28115821)
41. Efficacy, safety and acceptability of biphasic insulin aspart 30 in Indian patients with type 2 diabetes: results from the PRESENT study.
Sharma SK; Joshi SR; Kumar A; Unnikrishnan AG; Hoskote SS; Moharana AK; Chakkarwar PN; Vaz JA;
J Assoc Physicians India; 2008 Nov; 56():859-63. PubMed ID: 19263683
[TBL] [Abstract][Full Text] [Related]
42. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
44. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials.
Hanefeld M; Berria R; Lin J; Aronson R; Darmon P; Evans M; Van Gaal L
Adv Ther; 2014 Aug; 31(8):861-72. PubMed ID: 25143188
[TBL] [Abstract][Full Text] [Related]
45. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
Rodbard HW; Tripathy D; Vidrio Velázquez M; Demissie M; Tamer SC; Piletič M
Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
[TBL] [Abstract][Full Text] [Related]
46. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.
Khunti K; Damci T; Meneghini L; Pan CY; Yale JF;
Diabetes Obes Metab; 2012 Jul; 14(7):654-61. PubMed ID: 22443213
[TBL] [Abstract][Full Text] [Related]
47. Comparative effectiveness and safety of different basal insulins in a real-world setting.
Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
[TBL] [Abstract][Full Text] [Related]
48. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
Holman RR; Thorne KI; Farmer AJ; Davies MJ; Keenan JF; Paul S; Levy JC;
N Engl J Med; 2007 Oct; 357(17):1716-30. PubMed ID: 17890232
[TBL] [Abstract][Full Text] [Related]
49. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
Terauchi Y; Usami M; Inoue T
Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
[TBL] [Abstract][Full Text] [Related]
50. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
Gupta A
Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
[TBL] [Abstract][Full Text] [Related]
51. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.
Meneghini L; Mersebach H; Kumar S; Svendsen AL; Hermansen K
Endocr Pract; 2011; 17(5):727-36. PubMed ID: 21550957
[TBL] [Abstract][Full Text] [Related]
52. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
Belhadj M; Dahaoui A; Jamoussi H; Farouqi A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
[TBL] [Abstract][Full Text] [Related]
53. Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus.
Liu SC; Chuang SM; Wang CH; Chien MN; Lee CC; Chen WC; Leung CH; Lin JL
Diabetes Obes Metab; 2023 Mar; 25(3):700-706. PubMed ID: 36321411
[TBL] [Abstract][Full Text] [Related]
54. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
55. Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.
Chen L; Xing X; Lei M; Liu J; Shi Y; Li P; Qin G; Li C; Li Y; Wang Q; Gao T; Hu L; Wang Y; Yang W
Chin Med J (Engl); 2014; 127(2):208-12. PubMed ID: 24438605
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
57. A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).
Shimoda S; Sato M; Sekigami T; Motoshima H; Yoshimura R; Fukuda K; Matsuo Y; Noda H; Okubo M; Ichimori S; Fujisawa K; Fukunaga M; Araki E;
J Diabetes Investig; 2016 Sep; 7(5):703-10. PubMed ID: 27181264
[TBL] [Abstract][Full Text] [Related]
58. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
[TBL] [Abstract][Full Text] [Related]
59. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
60. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
